Experiment 66811
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Serenoa repens (ARECACEAE) |
| Citation | GERBER,GS:. (2000). SAW PALMETTO FOR THE TREATMENT OF MEN WITH LOWER URIANRY TRACT SYMPTOMS.. 163(5) |
| Amount utilized | |
| Compound isolated | |
| Disease | A LITERATURE SEARCH OF STUDIES THAT HAVE ASSESSED THE MECHANISM OF ACTION AND CLINICAL RESULTS OF SAW PALMETTO IN MEN WITH BENIGN PROSTATIC HYPERPLASIA WAS PERFORMED. A VARIETY OF POTENTIAL MECHANISMS OF ACTION OF SAW PALMETTO HAVE BEEN DEMOSTRATED THROUGH IN VITO STUDIES, INCLUDING 5-ALPHA REDUCTASE INHIBITION, ADRENERGIC RECEPTOR ANTAGONISM AND INTRAPROSTATIC ANDROGEN RECEPTOR BLOCKADE. CLINICAL EVIDENCE OF THE RELEVANCE OF THESE EFFECTS IS LARGELY UNAVAILABLE. THE USE OF SAW PALMETTO IN MEN WITH BENIGN PROSTATIC HYPERPALSIA IS SAFE WITH NO RECOGNIZED ADVERSE EFFECTS. NO EFFECT ON SERUM PROSTATE SPECIFIC ANTIGEN HAS BEEN NOTED. PLACEBO CONTROLLED TRIALS AND META-ANALYSES HAVE SUGGESTED THAT SAW PALMETTO LEADS TO SUBJECTIVE AND OBJECTIVE IMPROVEMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS. HOWEVER, MOST STUDIES ARE SIGNIFICANTLY LIMITED BY METHODOLOGICAL FLAWS, SMALL PATIENT NUMBERS AND BRIEF TREAMENT INTERVALS. EVIDENCE SUGGESTS THAT SAW PALMETTO MAY HAVE A SIGNIFICANT EFFECT ON URINARY FLOW RATES AND SYMPTOM SCORES COMPARED TO PLACEBO IN MEN WITH LOWER URINARY TRACT SYMPTOMS. HOWEVER, LARGE SCALE, PLACEBO CONTROLLED TRIALS ARE NEEDED TO ASSESS THE EFFICACY OF SAW PALMETTO. |
| Dose amount | VAR |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Extract | HEXANE EXT |
| Gender | MALE |